Financing a PE Portfolio Company Add-On Acquisition: How Borrowers Fund the Tuck-In Without Blowing Up the Revolver

You are the CFO of a private-equity-backed portfolio company. The sponsor calls on a Tuesday. They have found a bolt-on acquisition — a smaller competitor, complementary product line, same customer base — and want to close in eight weeks. The purchase price is $18 million. The target has $22 million of revenue, $3 million of EBITDA, and a modest amount of receivables and inventory. Your existing ABL revolver is $40 million with $22 million drawn. Your term loan sits at $25 million. Sponsor wants to know how you are going to finance it.

This is the add-on acquisition financing problem. It happens all the time in PE portfolio companies, and it is a specific enough scenario that the standard "how do I finance an acquisition" playbook does not quite apply. The borrower is not a first-time acquirer; there is an existing capital structure with an incumbent lender group. The sponsor has a return model that assumes a particular financing mix. And the timeline is tight because in PE, add-ons are usually already under LOI when the CFO gets the call.

This piece is for the CFO or head of finance at a PE portfolio company — and the sponsor deal team helping them — thinking through the actual financing options and what each one costs, both in dollars and in facility flexibility.

The five financing tools that show up in add-on deals

Add-on acquisitions are almost never financed from a single source. The typical structure combines two or three of the following, in proportions that depend on the target size, the incumbent lender's appetite, and the sponsor's willingness to write another check.

1. Accordion or incremental facility on the existing revolver

If the credit agreement has a pre-negotiated accordion — a right to increase the commitment by a defined amount, typically 25 to 50 percent of the original size — this is the cheapest and fastest path. The pricing is often fixed at closing, the diligence is a bring-down rather than a full re-underwriting, and the documentation is an amendment rather than a new credit agreement. Timeline is realistically two to four weeks if the incumbent has capacity and the accordion terms are administrative rather than discretionary. We wrote a full walkthrough of accordion mechanics in the accordion guide.

The catch is capacity. If the borrower already used part of the accordion or if the incumbent lender's hold appetite is capped, the accordion may not stretch to the full amount needed. If the target's collateral adds meaningfully to the borrowing base — the acquired A/R and inventory get folded in after closing — the accordion can be sized against that pickup and still be borrower-friendly.

2. Incremental term loan tranche

If the acquisition is being financed on a cash-flow basis rather than purely against acquired collateral, an incremental term loan tranche on the existing term loan can add fixed-rate or SOFR-based dollars specifically for the acquisition. Pricing typically resets on the incremental (it does not automatically inherit the existing tranche's rate), and there is often a most-favored-nation (MFN) provision that steps up existing tranche pricing if the incremental prices meaningfully above.

Incremental term loans are common in sponsor-backed structures because they preserve the revolver capacity for working-capital needs post-close. The revolver stays sized to operations; the term loan stack absorbs the acquisition dollars.

3. Seller paper

Seller notes — subordinated financing provided by the seller as part of the purchase price — are common in add-on deals and often underappreciated as a financing tool. Typical seller paper sits below the senior debt in the capital stack, carries interest that may be paid-in-kind (accrued rather than cash-paid) for the first year or two, and has a maturity behind the senior debt so it does not compete for prepayment.

Seller paper is cheap capital because the seller has an incentive to accept below-market terms to close the transaction, and it reduces the amount of senior debt or sponsor equity needed. For lenders it counts as a form of quasi-equity when structured properly (deeply subordinated, no cash pay for a defined period, no cross-defaults into the senior facility). Fifteen to twenty percent of the purchase price on seller paper is a reasonable range in a typical add-on deal.

4. Sponsor equity or preferred

The sponsor's model already assumes some incremental equity — the question is how much. In deals where the incumbent lender is being pushed on facility size, or where post-close leverage would breach existing covenants, sponsor equity fills the gap. This can be common equity at the same valuation as the sponsor's original investment, or preferred equity that sits between the debt and the common. Preferred is more common in add-ons because it preserves the sponsor's return math on the platform.

5. Full refinance

If the add-on is large relative to the platform — say, doubling the size of the business — or if the incumbent lender group cannot get comfortable with any of the incremental options, the alternative is refinancing the entire capital structure to a new, larger facility. This is the most expensive path in terms of transaction costs (closing fees, new field exam, new appraisals, legal, agent fees) but it resets the entire capital structure to fit the pro-forma company.

Refinancing at close of an add-on takes six to ten weeks, which usually does not fit an eight-week close timeline. The way this gets solved is with bridge financing — a short-term facility that closes at add-on close and gets replaced by the permanent facility three to six months later, once the pro-forma financials are stabilized and the market is ready.

How to pick the right combination for your deal

Two questions drive the choice.

Does the target bring collateral or just cash flow?

If the target has meaningful A/R and inventory — a distribution business, a manufacturer, a services company with billed and unbilled receivables — the incremental collateral supports incremental borrowing base availability post-close. The accordion or a revolver upsize is the natural tool because the acquired collateral funds part of the acquisition. In our packaging-company example, if the target has $4 million of eligible A/R and $2 million of eligible inventory, the pro-forma borrowing base picks up roughly $4 million (85 percent on A/R and 50 percent on inventory as a rough cut). That $4 million of incremental availability is financing without any new commitment.

If the target is asset-light — software, services with long collection cycles, brand-heavy consumer businesses — the acquired collateral is limited and the deal needs cash-flow financing. Incremental term loan, seller paper, and sponsor equity carry the load.

Where is the existing capital structure relative to lender comfort?

The existing facility has a leverage covenant, a fixed-charge coverage ratio, and probably a springing FCCR when availability drops. Model the pro-forma capital structure. If pro-forma leverage stays inside the existing covenants with reasonable headroom, the incumbent can layer on. If pro-forma leverage breaches, you need either sponsor equity to bring leverage down or a full refinance to reset the covenants.

The point is: the existing lender has already told you what they can live with by way of the covenants. Pro-forma against those covenants first. That tells you which combination of tools is actually available.

What lenders want to see before adding on to a facility

An incumbent lender considering an accordion or incremental term to fund an add-on will typically want:

• The target's audited or reviewed financials for the trailing two to three years. Not a projection deck.
• Target A/R and inventory detail at customer and SKU level for eligibility analysis. This is the field-exam scope on the target.
• Combined pro-forma financials showing pro-forma revenue, EBITDA, leverage, and coverage. Reasonable synergy assumptions if any, cleanly labeled and defensible.
• The purchase agreement and material schedules — key reps, indemnities, escrow, working-capital adjustment mechanics.
• Sponsor's equity commitment letter if additional equity is part of the sources and uses.
• Integration plan — who owns integration, what systems are consolidating, what customer or supplier concentration risks the combined company will have, what happens to the target's collections and cash management on Day 1.
• Sources and uses — the full picture. Where every dollar of purchase price comes from, and where the closing fees and transaction expenses come from.

What you should not lead with: synergy assumptions that assume the world. Lenders are underwriting the standalone target and the platform separately, then giving credit to combined economics only where the operational path is clear. Aggressive synergy stories can hurt more than help.

Timeline in an eight-week close

A realistic timeline for an accordion-plus-seller-paper structure looks like:

• Weeks 1-2: Package target financials, engage incumbent lender, kick off buy-side diligence (QoE, legal, ops).
• Weeks 2-4: Incumbent lender field exam and appraisal on target collateral. Commitment discussions in parallel with sponsor equity sizing.
• Weeks 4-6: Amendment and joinder documentation drafted. Seller-paper terms finalized. Sources and uses locked.
• Weeks 6-7: Final documentation, funding conditions confirmed, closing checklist.
• Week 8: Close.

The tight path is diligence on the target. If the target is well-run and has clean financials, this compresses. If the target has never been through a lender field exam, it takes longer than the two weeks the model assumes.

Where DCE fits

Don Clarke — SFNet Hall of Fame 2021, Lifetime Achievement Award, author of "Asset Based Lending Disciplines" (the first ABL textbook), and trainer of more than 5,000 professionals at GE Capital, JP Morgan Chase, Lloyds, and Barclays — spent decades structuring ABL facilities for growing and acquisitive middle-market borrowers, many of them PE-backed. DCE advises portfolio company CFOs and sponsors on the specific question of how to finance an add-on inside an existing capital structure: whether the incumbent lender has the capacity and comfort, whether the target collateral moves the needle on borrowing base, how to size sponsor equity against the debt tranches, when seller paper is worth pushing for, and when the transaction really requires a full refinance rather than an incremental. Because we are not the lender and not the sponsor, we can look at the deal from the CFO's chair — what is the cleanest capital structure that closes on time and works post-close.

ABLC (ablc.net) is DCE's sister firm serving lenders with due diligence, field examination, and training services — including target-side collateral diligence for lenders funding platform add-ons.

Related reading: our acquisition financing walkthrough, the sponsor-backed ABL structure guide, and the equity cure rights guide covering how sponsors preserve covenant compliance in stressed periods.

Educational only; not legal, tax, or investment advice. Every deal is specific to the platform, target, and lender group. Borrowers and sponsors should work with qualified counsel, accountants, and financial advisors on the transaction structure.